OncLive: ADCs emerge as exciting addition to ovarian cancer treatment
A class of drugs called antibody-drug coagulates (ADC) are designed with a specific target within the tumors that are not present within normal tissue. This targeted approach helps kill tumor cells while sparing healthy cells.
In late 2022, the FDA approved a new ADC called Mirvetuximab Soravtansine-gynx to treat certain types of ovarian cancer. Caroline Billingsley, MD, University of Cincinnati Cancer Center physician and associate professor in UC's College of Medicine, participated in a Q&A with publication OncLive to discuss the current state and future of ADCs in ovarian cancer treatment.
Billingsley said the FDA approval "gives us an exciting option for patients who have already seen a lot of chemotherapy and [experienced] a lot of toxicity.
"This is a drug that we can offer that [has more] limited toxicity and [exhibits] some efficacy. It’s an exciting time to adopt this drug into our treatment lines,” she continued.
Ongoing studies are researching Mirvetuximab Soravtansine-gynx as both a monotherapy and in combination with other treatments, Billingsley said.
"Given that it has a favorable toxicity profile, it’s an ideal drug to combine with other agents," she said.
Featured photo at top of ovarian cancer tumor in animal model courtesy of National Cancer Institute.
Related Stories
These teeny spiders are social media stars
August 28, 2026
The New York Times turned to a University of Cincinnati professor to explain the appeal of jumping spiders on social media.
An internal divide among unions on AI impacts the Wisconsin gubernatorial race
August 28, 2026
Anne Lofaso, a professor in the Donald P. Klekamp College of Law at UC, spoke with Wisconsin Public Radio, about the schism among unions over AI and whether it is a plus, a negative, or somewhere in between when looking at job creation.
On-site training in Speech & Hearing Clinic sets UC’s programs apart
August 27, 2026
At the University of Cincinnati’s Speech & Hearing Clinic, Doctor of Audiology and Speech-Language Pathology graduate students gain real-world experience while providing free speech and hearing services to the community.